Introduction:
Still’s Disease is characterized by systemic inflammation, recurrent fevers, and arthritis. It poses significant challenges in management, particularly when complications such as hepatitis arise. Initial treatment often involves IL-6 receptor inhibition with Tocilizumab, as supported by clinical trials [1] and the use of rituximab as an alternative [2]. We present a complex case where these therapies were employed sequentially with varying outcomes.